REPLY: Shareholders’ Meeting approves the 2020 Financial Statements
26.4.2021 15:07:00 EEST | Business Wire | Press release
The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2020, confirming the distribution of a gross dividend of €0.56 per share.
The dividend will be paid on 5 May 2021, with dividend date set on 3 May 2021 (record date on 4 May 2021).
2020 Financial Statement
The Reply Group closed the 2020 financial year with a consolidated turnover of €1,250.2 million, recording a 5.7% increase compared to €1,182.5 million for the 2019 financial year.
Consolidated EBITDA was €207.9 million, up 8.7% compared to €191.3 million in 2019.
Consolidated EBIT, from January to December, was €169.5 million, up 9.1% compared to €155.3 million at December 2019.
The Group net profit was at €123.6 million, up 8.6% compared to €113.9 million recorded in 2019.
The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposal of the Board of Directors:
Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023
The Shareholders’ Meeting appointed the new members to the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023 based on the submitted list of candidates.
The following have been appointed as Directors:
- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Daniele Angelucci, Marco Cusinato, Elena Previtera and Patrizia Polliotto (who declared to comply with the independence requirements set forth in article 148 of the TUF [Testo unico sulla finanza – Financial Act] and the Corporate Governance Code), drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (76.709% of votes obtained);
- Secondina Giulia Ravera and Francesco Umile Chiappetta, who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital).
The appointed Board of Statutory Auditors consists of three standing members and two alternates:
- Ciro Di Carluccio (Chairman) and Giancarla Branda (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital);
- Piergiorgio Re (Standing Auditor), Ada Garzino Demo (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (75.741% of votes obtained).
- The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current legislation, are available in the investors’ section of the company website www.reply.com
Approval of the Programme for the Acquisition and/or Disposal of Own Shares
The Shareholders’ Meeting authorised a new share buyback programme, while withdrawing the current one approved at the Shareholders’ Meeting of 21 April 2020: the main objective of this programme is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.
The authorization has a duration of 18 months from the date of the resolution, for a maximum of 7,411,457 ordinary shares (equal to 19.8107% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €963,489.41, within the limit of a maximum financial commitment of €300,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.
Approval of the Remuneration Report
The Shareholders' Meeting also approved Section II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.
Approval of the delegation of powers to the Board of Directors to increase the share capital with a share premium, subject to withdrawal of the previous delegation of powers granted on 21 April 2016
The Shareholders' Meeting withdrew the mandate conferred to the Board of Directors to increase the share capital, which expired on April 21, 2021, and reauthorized the Board of Directors, in compliance to article 2443 of the Italian Civil Code, to increase the share capital with a share premium and the exclusion of shareholders' option rights in compliance to article 2441, paragraph 4, up to a maximum nominal amount of 390,000.00 Euros through the issue of a maximum of 3,000,000 new Reply S.p.A. ordinary shares with a nominal value of 0.13 Euros each, to be executed in one or more tranches, therefore in a divisible manner, for a maximum period of five years, to be paid through contributions in kind of shares in other companies, having a similar or analogous purpose to the company's or in any case functional to the development of the business. The Shareholders' Meeting consequently resolved to amend Article 5 (Share Capital) of the Articles of Association
The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services www.reply.com
April 26, 2021
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005462/en/
Contact information
Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Investor Relation Contacts
Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
